Healthcare is experiencing a transformative shift as digital therapeutics move from experimental tools to prescribed medical treatments. Just as doctors prescribe medications, they can now prescribe evidence-based digital health applications that deliver therapeutic interventions through software. This paradigm represents a fundamental revolution in medical practice, where digital therapeutics (DTx) function as “prescription medicine in app form” or “software as medicine (SaM)“.
The concept treats digital health applications with the same rigor as traditional pharmaceuticals—requiring clinical evidence, regulatory approval, and integration into existing healthcare workflows. Unlike the thousands of wellness apps available for general download, prescribed digital therapeutics undergo rigorous clinical validation, regulatory review, and safety assessment before doctors can prescribe them to patients.
Germany’s DiGA: The Pioneer Model
Germany established the world’s first comprehensive national program for prescribed digital health applications through its Digital Health Applications (DiGA) program in 2020. The program allows doctors and psychotherapists to prescribe certified digital health apps that are reimbursed by statutory health insurance, creating the first truly integrated “apps on prescription” system.
How DiGA Works
The German model operates through a fast-track assessment process managed by the Federal Institute for Drugs and Medical Devices (BfArM). Digital health applications must demonstrate:
- CE marking as medical devices (Class I, IIa, or IIb)
- Positive health effects or medical benefits
- Strict data protection and security standards
- User-friendliness and interoperability requirements
Once approved, DiGAs are listed in an official national directory, enabling doctors to prescribe them just like traditional medications. Patients receive a prescription code, download the app, and access the full therapeutic program—all covered by their health insurance.
By September 2023, over 374,000 DiGA prescriptions had been activated, demonstrating real-world adoption and clinical integration.
Global Adoption of the Prescription Model
The German DiGA model has inspired similar programs worldwide, each adapted to local healthcare systems and regulatory frameworks.
European Implementations
Belgium has developed a three-level mHealth validation pyramid where digital health applications progress through increasing levels of validation. Level 3+ applications achieve full reimbursement within specific care pathways, with seven apps currently approved for chronic heart failure management.
France launched its PECAN (Prise en Charge Anticipée Numérique) pathway in March 2024, directly inspired by DiGA. The system provides fast-track reimbursement for one year with fixed rates (€435 initial fee, then €38.3 monthly), allowing early access while gathering additional clinical evidence.
The United Kingdom has established the NICE Evidence Standards Framework for digital health technologies, creating risk-based evidence tiers that determine reimbursement eligibility based on clinical impact and economic value.
North American Approaches
The United States has developed a regulatory pathway for Prescription Digital Therapeutics (PDTs) through the FDA, with thirteen products currently cleared including treatments for substance use disorders, ADHD, and anxiety. However, reimbursement remains fragmented across different payers, creating access challenges.
Canada is exploring enhanced pathways through CADTH’s time-limited reimbursement categories, though these focus primarily on pharmaceuticals rather than digital therapeutics specifically.
Asia-Pacific Innovation
Japan has successfully integrated digital therapeutics into its national health insurance system, approving and reimbursing products like CureApp SC for nicotine addiction and CureApp HT for hypertension under its Software as Medical Device framework.
Australia provides DTx reimbursement through multiple existing pathways including the Pharmaceutical Benefits Scheme and Medical Benefits Schedule, demonstrating how digital therapeutics can integrate into established healthcare infrastructure.
Comparative Analysis of Global Approaches
The following table summarizes the key characteristics and differences between major digital therapeutic prescription programs worldwide:
| COUNTRY | PROGRAM TYPE | AUTHORATORY | CLASSIFICATION | ASSESSMENT TIMELINE | EVIDENCE REQUIREMENTS | REIMBURSEMENT MODEL | PRESCRIPTION Method | DATA PROTECTION REQUIREMENTS | CURRENT STATUS |
| Germany (DiGA) | National fast-track system | BfArM (Federal Institute) | Class I, IIa, IIb (recent) | Up to 3 months | Positive health effect or medical benefit | Direct app reimbursement | Direct prescription by doctors | Strict GDPR compliance | Fully operational since 2020 |
| Belgium (mHealth Pyramid) | Three-level validation pyramid | FAMHP + NIHDI | CE marked medical device | Varies by level | Socio-economic benefit (Level 3) | Care pathway integration | Within care pathways | GDPR compliance required | Operational with 7 apps at Level 3+ |
| France (PECAN) | Fast-track inspired by DiGA | ANS + CNEDiMTS | Medical device required | 1 year provisional | Clinical evidence after 1 year | Fixed rates (€435 + €38.3/month) | Prescription required | Data protection mandatory | Launched March 2024 |
| United Kingdom (NICE DTF) | Evidence-based framework | NICE | Risk-based tiers (A, B, C) | Varies by tier | Tier-based evidence levels | Economic evaluation required | Clinical recommendation | Data security standards | Framework established |
| United States (FDA PDT) | FDA regulatory pathway | FDA | Various FDA classes | Varies by pathway | Safety and efficacy data | Fragmented payer coverage | Prescription required | HIPAA and FDA standards | Multiple PDTs approved |
| Japan (SaMD) | National insurance coverage | MHLW | SaMD framework | Standard review process | Clinical evidence required | National health insurance | Prescription by physicians | Privacy law compliance | Several DTx approved |
| Australia (Multiple Pathways) | Multiple existing schemes | TGA | SaMD framework | Varies by pathway | Varies by pathway | PBS/MBS integration | Various methods | Privacy Act compliance | Operational across schemes |
| Netherlands | Substitution-based coverage | Healthcare insurers | Medical device if applicable | No specific timeline | Evidence if substituting care | Substitution coverage | Clinical recommendation | GDPR compliance | Limited implementation |
Common Elements and Divergent Approaches
Universal Commonalities
All successful prescription digital therapeutic programs share several fundamental characteristics:
- Medical device regulation requiring CE marking or equivalent certification
- Clinical evidence requirements demonstrating safety and efficacy
- Data protection mandates ensuring patient privacy and security
- Healthcare provider involvement in prescription and monitoring processes
- Integration with existing healthcare systems rather than parallel structures
Key Differences
- Regulatory Speed: Germany and France offer fast-track assessments (3 months and 1 year respectively), while other countries use standard medical device approval timelines.
- Evidence Thresholds: Requirements range from Germany’s “positive health effect” to the UK’s tier-based evidence levels and the US’s varying FDA pathway requirements.
- Reimbursement Models: Countries either reimburse the digital solution directly (Germany, France) or integrate it within care pathways (Belgium) or existing benefit schemes (Australia).
- Prescription Integration: Some systems enable direct prescription like traditional medications (Germany, US), while others embed digital therapeutics within broader care protocols (Belgium, Netherlands).
The Future of Digital Prescribing
The prescription digital therapeutic model represents a fundamental shift toward evidence-based digital medicine that complements rather than replaces traditional treatments. As more countries develop regulatory frameworks and reimbursement pathways, digital therapeutics are becoming legitimate medical interventions that doctors can confidently prescribe alongside conventional therapies.
This evolution transforms smartphones and digital devices from consumer gadgets into legitimate medical tools, enabling continuous, personalized therapeutic interventions that extend far beyond the traditional clinic visit. The success of pioneering programs like Germany’s DiGA demonstrates that when properly regulated and integrated, digital therapeutics can enhance patient outcomes while improving healthcare accessibility and efficiency.
Need more information or just want a chat about your DTx Solution ideas
The PEP Health team has substantial experience designing, developing and deploying DTx solutions. For more information about how the PEP Health platform can help with your DTx solutions, contact our friendly and knowledgeable team at info@pep.health
Recent Comments